Inotrem announces positive outcome of interim futility analysis for its Phase IIB ASTONISH trial in septic shock patients to demonstrate nangibotide efficacy
June 10, 2021
Paris. June 10th, 2021. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today that the ASTONISH